Vahit Özmen1, Sibel Ö Gürdal2, Neslihan Cabioğlu1, Beyza Özcinar1, A Nilüfer Özaydın3, Arda Kayhan4, Erkin Arıbal5, Cennet Sahin6, Pınar Saip7, Oğuzhan Alagöz8. 1. Department of Surgery, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkey. 2. Departments of Surgery, Namık Kemal University School of Medicine, Tekirdağ, Turkey. 3. Department of Public Health, Marmara University School of Medicine, İstanbul, Turkey. 4. Departments of Radiology, University Health Sciences, İstanbul Kanuni Sultan Süleyman Training and Research Hospital, İstanbul, Turkey. 5. Department of Radiology, Marmara University School of Medicine, İstanbul, Turkey. 6. Department of Radiology, University Health Sciences, İstanbul Şisli Hamidiye Etfal Training and Research Hospital, İstanbul, Turkey. 7. Department of Medical Oncology, İstanbul University School of Medicine, İstanbul, Turkey. 8. Department of Industrial & Systems Engineering and Population Health Sciences, UW Carbone Cancer Center, University of Wisconsin Hospital and Clinics, Madison, WI, USA.
Abstract
OBJECTIVE: We used the results from the first three screening rounds of Bahcesehir Mammography Screening Project (BMSP), a 10-year (2009-2019) and the first organized population-based screening program implemented in a county of Istanbul, Turkey, to assess the potential cost-effectiveness of a population-based mammography screening program in Turkey. MATERIALS AND METHODS: Two screening strategies were compared: BMSP (includes three biennial screens for women between 40-69) and Turkish National Breast Cancer Registry Program (TNBCRP) which includes no organized population-based screening. Costs were estimated using direct data from the BMSP project and the reimbursement rates of Turkish Social Security Administration. The life-years saved by BMSP were estimated using the stage distribution observed with BMSP and TNBCRP. RESULTS: A total of 67 women (out of 7234 screened women) were diagnosed with breast cancer in BMSP. The stage distribution for AJCC stages O, I, II, III, IV was 19.4%, 50.8%, 20.9%, 7.5%, 1.5% and 4.9%, 26.6%, 44.9%, 20.8%, 2.8% with BMSP and TNBCRP, respectively. The BMSP program is expected to save 279.46 life years over TNBCRP with an additional cost of $677.171, which implies an incremental cost-effectiveness ratio (ICER) of $2.423 per saved life year. Since the ICER is smaller than the Gross Demostic Product (GDP) per capita in Turkey ($10.515 in 2014), BMSP program is highly cost-effective and remains cost-effective in the sensitivity analysis. CONCLUSION: Mammography screening may change the stage distribution of breast cancer in Turkey. Furthermore, an organized population-based screening program may be cost-effective in Turkey and in other developing countries. More research is needed to better estimate life-years saved with screening and further validate the findings of our study.
OBJECTIVE: We used the results from the first three screening rounds of Bahcesehir Mammography Screening Project (BMSP), a 10-year (2009-2019) and the first organized population-based screening program implemented in a county of Istanbul, Turkey, to assess the potential cost-effectiveness of a population-based mammography screening program in Turkey. MATERIALS AND METHODS: Two screening strategies were compared: BMSP (includes three biennial screens for women between 40-69) and Turkish National Breast Cancer Registry Program (TNBCRP) which includes no organized population-based screening. Costs were estimated using direct data from the BMSP project and the reimbursement rates of Turkish Social Security Administration. The life-years saved by BMSP were estimated using the stage distribution observed with BMSP and TNBCRP. RESULTS: A total of 67 women (out of 7234 screened women) were diagnosed with breast cancer in BMSP. The stage distribution for AJCC stages O, I, II, III, IV was 19.4%, 50.8%, 20.9%, 7.5%, 1.5% and 4.9%, 26.6%, 44.9%, 20.8%, 2.8% with BMSP and TNBCRP, respectively. The BMSP program is expected to save 279.46 life years over TNBCRP with an additional cost of $677.171, which implies an incremental cost-effectiveness ratio (ICER) of $2.423 per saved life year. Since the ICER is smaller than the Gross Demostic Product (GDP) per capita in Turkey ($10.515 in 2014), BMSP program is highly cost-effective and remains cost-effective in the sensitivity analysis. CONCLUSION: Mammography screening may change the stage distribution of breast cancer in Turkey. Furthermore, an organized population-based screening program may be cost-effective in Turkey and in other developing countries. More research is needed to better estimate life-years saved with screening and further validate the findings of our study.
Entities:
Keywords:
Mammography screening; breast cancer screening Turkey; cost-effectiveness of breast cancer screening
Authors: Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Danny R Youlden; Susanna M Cramb; Nathan A M Dunn; Jennifer M Muller; Christopher M Pyke; Peter D Baade Journal: Cancer Epidemiol Date: 2012-03-27 Impact factor: 2.984
Authors: Christoph I Lee; Mucahit Cevik; Oguzhan Alagoz; Brian L Sprague; Anna N A Tosteson; Diana L Miglioretti; Karla Kerlikowske; Natasha K Stout; Jeffrey G Jarvik; Scott D Ramsey; Constance D Lehman Journal: Radiology Date: 2014-10-28 Impact factor: 11.105
Authors: Quirine Lamberts Okonkwo; Gerrit Draisma; Arno der Kinderen; Martin L Brown; Harry J de Koning Journal: J Natl Cancer Inst Date: 2008-09-09 Impact factor: 13.506
Authors: Ajeng V Icanervilia; Jurjen van der Schans; Qi Cao; Adriana C de Carvalho; Kathya Cordova-Pozo; Jarir At Thobari; Maarten J Postma; Antoinette DI van Asselt Journal: J Glob Health Date: 2022-07-16 Impact factor: 7.664